Kraematon Investment Advisors Inc. Has $901,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Kraematon Investment Advisors Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 995 shares of the company’s stock after selling 24 shares during the period. Kraematon Investment Advisors Inc.’s holdings in Eli Lilly and Company were worth $901,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. Lynx Investment Advisory purchased a new stake in shares of Eli Lilly and Company during the second quarter worth $32,000. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $26,000. Core Wealth Advisors Inc. grew its stake in shares of Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares in the last quarter. Activest Wealth Management bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $39,000. Finally, Tidemark LLC acquired a new position in Eli Lilly and Company in the fourth quarter worth approximately $29,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the sale, the insider now owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,214,704 shares of company stock valued at $1,066,841,316. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY stock traded up $46.37 on Friday, reaching $891.68. 6,587,628 shares of the company were exchanged, compared to its average volume of 3,089,428. The firm has a market capitalization of $847.46 billion, a PE ratio of 131.32, a PEG ratio of 1.81 and a beta of 0.41. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $966.10. The stock’s fifty day moving average price is $871.07 and its 200 day moving average price is $796.61. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.58%. Eli Lilly and Company’s payout ratio is 76.58%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on LLY. Bank of America lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $850.00 to $1,000.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Jefferies Financial Group raised their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Barclays boosted their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Finally, Argus increased their price objective on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Three equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $916.53.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.